FibroBiologics, Inc. FBLG 深 滬
已收盤 02-06 16:00:00 美东时间
0.2517
+0.025
+10.83%
華盛通- 最 高0.266
- 今 開0.2322
- 成交量 72.71万股
- 最 低 0.2312
- 昨 收 0.2271
- 總市值 1674.30万
- 52周最高 1.53
- 市盈率 靜 --
- 換手率 1.09%
- 52周最低 0.2201
- 委 比 -90.66%
- 總股本 6651.97万
- 歷史最高 55.00
- 量 比 0.39
- 振 幅 15.32%
- 歷史最低 0.2201
- 每 手 1
- 風險率 0.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FibroBiologics Issued Canadian IP Office Patent
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for
02-05 21:38
Why Align Technology Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Shares of Align Technology Inc (NASDAQ:ALGN) rose sharply in pre-market trading...
02-05 17:34
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
美股大行评级 | 杰富瑞上调百度目标价从159美元升至181美元；花旗下调京东目标价从44美元下调至37美元
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从47美元升至48美元；BTIG：维持Hudson Pacific Properties"买入"评级，目标价从4.75美元升至26美元
01-05 13:52
FibroBiologics Announces The Filing Of A Phase 1/2 IND Application With The U.S. FDA Seeking Regulatory Clearance To Initiate Clinical Trials Of CYPS317, An Investigational Allogeneic Fibroblast Spheroid-Based Therapy For The Treatment Of Moderate To Severe Psoriasis
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases
2025-12-31 21:33
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Lexaria Bioscience (NASDAQ:LEXX) stock increased by 6.5% to $0.89 durin...
2025-12-17 05:05
FibroBiologics announces $1.7M registered direct offering
FibroBiologics (NASDAQ:FBLG) announced on Monday that it has entered into an agreement for the issuance and sale of an aggregate of 5.23M shares of its common stock at an offering price of $0.33 per s...
2025-12-15 21:56
FibroBiologics Files New USPTO Patent For Fibroblast-Derived Spheroid Platform Aimed At Cartilage And Disc Repair
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for
2025-12-10 21:35
FibroBiologics Announces That It Has Fully Repaid All Outstanding Amounts Under Its Convertible Promissory Notes Issued To Yorkville
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for
2025-11-26 21:35
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
2025-11-21 15:50
